| Literature DB >> 35053015 |
Zhi Sen Tan1, Alexiaa Sim1, Masato Kawabata1, Stephen F Burns1.
Abstract
Caffeine is an ergogenic aid in many sports, including basketball. This systematic review examines the effects of caffeine on basketball-related skill tasks along with physical aspects of performance deemed important for the game. A systematic search was conducted across three databases (PubMed, SPORTDiscus and Web of Science) to identify randomized-controlled trials which examined the effect of caffeine on basketball performance outcomes including: free-throw, 3-point shooting accuracy, dribbling speed, vertical jump height, and linear and repeated sprints. Forty-six articles were identified of which 10 met the inclusion criteria. Improvements in vertical jump were identified in four of five studies, agility in two of four studies, and in linear and repeated sprints in two of three studies. No deterioration in basketball skills performance was observed in any studies. It is suggested that caffeine is useful for basketball players to improve the physical aspects of their game-play performance but there is little evidence of any change in skill-based performance at present. Further research should clarify the effects of caffeine on basketball performance in women and the role of individual genetic variation on caffeine metabolism. Basketball players and coaches should be aware of the properties of caffeine before ingesting it as an ergogenic supplement.Entities:
Keywords: agility; dribbling; jump-height; shooting; skill; sports-specific; sprints
Year: 2021 PMID: 35053015 PMCID: PMC8773249 DOI: 10.3390/biology11010017
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1Search strategy and study selection process using PRISMA guidelines.
Figure 2Cochrane Risk-of-Bias (RoB 2) tool.
Physiotherapy Evidence Database (PEDro) scale.
| PEDro Criterion | Abian-Vicen et al., 2014 [ | Cheng et al., 2016 [ | Puente et al., 2018 [ | Puente et al., 2017 [ | Raya-Gonzalez et al., 2021 [ | Scanlan et al., 2019 [ | Stojanovic et al., 2021 [ | Stojanovic et al., 2019 [ | Tan et al., 2020 [ | Tucker et al., 2013 [ |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 * | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 7 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 8 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 9 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 10 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 9/10 | 9/10 | 9/10 | 9/10 | 9/10 | 9/10 | 9/10 | 9/10 | 6/10 | 6/10 |
Criterion in the PEDro scale: 1= eligibility criteria; 2 = random allocation of subjects; 3 = concealed allocation; 4 = baseline comparability of important measures; 5 = blinding of subjects; 6 = blinding of therapists; 7 = blinding of assessors; 8 = measures obtained for >85% subjects; 9 = intention-to-treat analysis; 10 = between -group statistical comparisons; 11 = point measures and measures of variability. * Does not contribute to the total PEDro score. A score of ‘1’ indicates that the criterion is met while a score of ‘0′ indicates that the criterion is not met.
Effect of caffeine supplementation on basketball skills performance.
| References | Participant Profile | Intervention | Administration Mode | Ingestion Time (min) | Measures (Units) & Change | CAF | PLA |
| Hedge’s |
|---|---|---|---|---|---|---|---|---|---|
| Abian-Vicen et al., 2014 | 16 males [age: 14.9 ± 0.8 years; body mass = 73.4 ± 12.4 kg; height = 182.3 ± 6.5 cm]; National Spanish League first division junior team | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Energy drink powder dissolved in 250 mL water | 60 | Free-throw (%): – | 70.3 ± 11.8 | 70.7 ± 11.8 | 0.45 | −0.03 |
| 3-point score (%): – | 39.9 ± 11.8 | 38.1 ± 12.8 | 0.33 | 0.15 | |||||
| Puente et al., 2017 | 10 males [age: 27.1 ± 4.0 years] and 10 females [age: 27.9 ± 6.1 years]; professional and semi-professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule | 60 | Free-throw score during | ||||
| basketball-specific testing: – | 15.6 ± 2.3 | 15.4 ± 1.6 | 0.39 | 0.10 | |||||
| CODAT (s): | |||||||||
| With the ball: – | 6.14 ± 0.32 | 6.20 ± 0.29 | 0.12 | −0.20 | |||||
| Notational Analysis – | |||||||||
| 2-point field goals made: – | 2.7 ± 2.6 | 2.5 ± 2.4 | 0.37 | 0.08 | |||||
| 2-point field goals attempted: – | 4.5 ± 3.3 | 3.8 ± 3.0 | 0.21 | 0.22 | |||||
| Accuracy in 2-point field goals (%): – | 52.9 ± 37.2 | 54.7 ± 30.5 | 0.45 | −0.05 | |||||
| 3-point field goals made: – | 0.8 ± 1.1 | 0.9 ± 1.2 | 0.27 | −0.09 | |||||
| 3-point field goals attempted: – | 2.4 ± 2.3 | 2.8 ± 2.1 | 0.23 | −0.18 | |||||
| Accuracy in 3-point field goals (%): – | 23.7 ± 27.5 | 27.4 ± 31.5 | 0.33 | −0.13 | |||||
| Free-throws made: ↑ * | 1.1 ± 1.1 | 0.6 ± 0.8 | 0.03 | 0.53 | |||||
| Free-throws attempted: ↑ * | 1.5 ± 1.5 | 0.9 ± 1.1 | 0.04 | 0.46 | |||||
| Accuracy in free-throws (%): – | 73.8 ± 20.7 | 71.4 ± 40.5 | 0.44 | 0.08 | |||||
| Scanlan et al., 2019 | 11 males and 10 females [age = 18.3 ± 3.3 years; body mass = 72.6 ± 7.5 kg; height = 180.3 ± 7.2 cm]; elite level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced; randomized, crossover design | Capsule with 250 mL water | 60 | Total dribble time (s): | ||||
| 5 m: – | 1.16 ± 0.08 | 1.17 ± 0.10 | 0.34 | −0.14 | |||||
| 10 m: – | 2.00 ± 0.13 | 2.01 ± 0.13 | 0.64 | −0.08 | |||||
| 20 m: – | 3.53 ± 0.21 | 3.56 ± 0.18 | 0.33 | −0.16 | |||||
| Dribble deficit (s): | |||||||||
| 5 m: – | 0.03 ± 0.10 | 0.01 ± 0.11 | 0.21 | 0.20 | |||||
| 10 m: – | 0.07 ± 0.09 | 0.03 ± 0.10 | 0.17 | 0.42 | |||||
| 20 m: – | 0.15 ± 0.13 | 0.15 ± 0.14 | 0.89 | 0.04 | |||||
| Stojanović et al., 2019 | 10 females [age: 20.2 ± 3.9 years; body mass: 69.2 ± 6.3 kg; height 175.4 ± 5.9 cm]; professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Linear sprint time (s): | ||||
| 5 m dribbling sprint: – | 1.20 ± 0.05 | 1.22 ± 0.08 | 0.45 | −0.31 | |||||
| 10 m dribbling sprint: – | 2.05 ± 0.12 | 2.07 ± 0.11 | 0.55 | −0.17 | |||||
| 20 m dribbling sprint: – | 3.56 ± 0.25 | 3.65 ± 0.15 | 0.15 | −0.45 | |||||
| Stojanović et al., 2021 | 11 males [age: 16.5 ± 1.0 years; body mass: 75.7 ± 7.4 kg; height: 184.7 ± 5.0 cm]; national youth level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Morning | ||||
| Repeated-sprint performance (s): | |||||||||
| Suicide run with dribbling time: – | 28.50 ± 2.06 | 29.04 ± 2.25 | 0.62 | −0.23 | |||||
| Evening | |||||||||
| Repeated-sprint performance (s): | |||||||||
| Suicide run with dribbling time: – | 32.65 ± 2.01 | 32.35 ± 1.93 | 0.62 | 0.14 | |||||
| Tan et al., 2020 | 12 males [age: 23.1 ± 1.9 years; body mass: 77.1 ± 12.4 kg; height: 180.1 ± 8.8 cm] and six females [age: 22.0 ± 1.3 yr; body mass: 67.0 ± 11.1 kg; height: 169.4 ± 8.9 cm]; college level | 6 mg per kg BM CAF or PLA; single-blind, randomized design | Caffeine powder dissolved in 300 mL water | 60 | Free-throw scores: – | 6.1 ± 1.7 | 5.5 ± 2.0 | 0.34 | 0.32 |
Data are reported as mean ± SD. CAF caffeine, PLA placebo, BM body mass, ES effect size, CODAT change of direction and acceleration test, – no change, ↑ increased, * significant change.
Effect of caffeine supplementation on physical performances of basketball players.
| References | Participant Profile | Intervention | Administration Mode | Ingestion Time (min) | Measures (Units) & Change | CAF | PLA |
| Hedge’s |
|---|---|---|---|---|---|---|---|---|---|
| Abian-Vicen et al., 2014 | 16 males [age: 14.9 ± 0.8 years; body mass = 73.4 ± 12.4 kg; height = 182.3 ± 6.5 cm]; National Spanish League first division junior team | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Energy drink powder dissolved in 250 mL water | 60 | CMJ without arm swing (cm): ↑ * | 38.3 ± 4.4 | 37.5 ± 4.4 | <0.05 | 0.18 |
| Mean power output (W/kg): – | 30.4 ± 2.8 | 30.1 ± 3.5 | 0.32 | 0.10 | |||||
| Peak power output (W/kg): – | 53.9 ± 5.0 | 53.8 ± 5.5 | 0.45 | 0.02 | |||||
| RJ-15 (cm): ↑ * | 30.2 ± 3.6 | 28.8 ± 3.4 | <0.05 | 0.40 | |||||
| Leg muscle power output (W/kg): ↑ * | 51.4 ± 5.7 | 49.4 ± 4.6 | <0.05 | 0.39 | |||||
| Yo-Yo IR-1 test (m): – | 2000 ± 706 | 1925 ± 702 | 0.19 | 0.11 | |||||
| Cheng et al., 2016 | 15 males [age: 20 ± 2 years; body mass: 84 ± 12 kg; 188 ± 6 cm]; Division I college level | 6 mg per kg BM CAF or PLA; double-blind, randomized, crossover design | Capsule with 200 mL water | 60 | VO2peak: – | 48.0 ± 7.5 | 49.2 ± 6.3 | >0.05 | −0.17 |
| EP (W): – | 242 ± 37 | 244 ± 42 | NS | −0.05 | |||||
| WEP (kJ): ↑ * | 13.4 ± 3.0 | 12.1 ± 2.7 | <0.05 | 0.46 | |||||
| Peak power (W): – | 538 ± 60 | 537 ± 49 | NS | 0.02 | |||||
| Mean power (W): – | 316 ± 34 | 311 ± 38 | NS | 0.14 | |||||
| Total work (kJ): | 56.9 ± 6.2 | 56.0 ± 6.9 | NS | 0.14 | |||||
| PO30 (W): – | 472 ± 45 | 471 ± 43 | NS | 0.02 | |||||
| PO60 (W): ↑ * | 419 ± 37 | 410 ± 38 | <0.05 | 0.24 | |||||
| PO90 (W): ↑ * | 377 ± 35 | 368 ± 37 | <0.05 | 0.25 | |||||
| PO120 (W): ↑ * | 349 ± 34 | 341 ± 38 | <0.05 | 0.22 | |||||
| PO150 (W): – | 330 ± 35 | 324 ± 38 | 0.09 | 0.16 | |||||
| FR (/s): ↑ * | 0.024 ± 0.007 | 0.029 ± 0.006 | 0.01 | −1.23 | |||||
| Puente et al., 2017 | 10 males [age: 27.1 ± 4.0 years] and 10 females [age: 27.9 ± 6.1 years]; professional and semi-professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule | 60 | Abalakov jump (cm): ↑ * | 38.2 ± 7.4 | 37.3 ± 6.8 | 0.012 | 0.13 |
| CODAT (s): | |||||||||
| Without the ball: – | 5.95 ± 0.31 | 5.96 ± 0.29 | 0.388 | −0.03 | |||||
| Raya-González et al., 2021 | 14 males [age: 21 ± 2 years; body mass: 87 ± 6 kg; height 190 ± 5 cm]; professional level | 6 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized, crossover design | Supplement dissolved in 250 mL water | 60 | Fitness tests: | ||||
| CMJ without arm swing (cm): ↑ * | 39.49 ± 5.28 | 37.09 ± 5.14 | 0.02 | 0.46 | |||||
| 20 m sprint (s): ↑ * | 3.05 ± 0.15 | 3.22 ± 0.15 | <0.001 | −1.13 | |||||
| Lane Agility Drill time (s): ↑ * | 11.56 ± 0.57 | 12.13 ± 0.82 | <0.001 | −0.82 | |||||
| Total RSA performance (s): ↑ * | 33.53 ± 1.33 | 35.23 ± 1.62 | <0.001 | −1.15 | |||||
| Best individual RSA (s): ↑ * | 5.50 ± 0.22 | 5.75 ± 0.27 | <0.001 | −1.02 | |||||
| Stojanović et al., 2019 | 10 females [age: 20.2 ± 3.9 years; body mass: 69.2 ± 6.3 kg; height 175.4 ± 5.9 cm]; professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Jump height (cm): | ||||
| CMJ without arm swing: – | 29.20 ± 4.39 | 27.92 ± 4.24 | 0.10 | 0.30 | |||||
| CMJ with arm swing: – | 35.14 ± 5.08 | 33.85 ± 3.92 | 0.15 | 0.29 | |||||
| Squat jump: – | 27.22 ± 4.37 | 25.97 ± 3.16 | 0.08 | 0.33 | |||||
| Change-of-direction time (s): | |||||||||
| Lane Agility Drill time: – | 12.99 ± 0.86 | 13.22 ± 0.87 | 0.12 | −0.27 | |||||
| Linear sprint time (s): | |||||||||
| 5 m sprint: – | 1.18 ± 0.11 | 1.24 ± 0.15 | 0.13 | −0.46 | |||||
| 10 m sprint: ↑ * | 2.01 ± 0.13 | 2.11 ± 0.18 | 0.05 | −0.65 | |||||
| 20 m sprint: ↑ * | 3.49 ± 0.23 | 3.59 ± 0.25 | 0.04 | −0.42 | |||||
| Repeated sprint performance (s): | |||||||||
| Suicide run time: – | 31.80 ± 1.62 | 32.20 ± 1.74 | 0.28 | −0.24 | |||||
| Stojanović et al., 2021 | 11 males [age: 16.5 ± 1.0 years; body mass: 75.7 ± 7.4 kg; height: 184.7 ± 5.0 cm]; national youth level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Morning | ||||
| Jump height (cm): | |||||||||
| CMJ without arm swing: ↑ * | 33.90 ± 5.38 | 31.03 ± 4.98 | <0.001 | 0.51 | |||||
| CMJ with arm swing: ↑ * | 42.32 ± 5.69 | 39.98 ± 5.23 | <0.001 | 0.40 | |||||
| Squat jump: ↑ * | 33.20 ± 4.71 | 30.55 ± 4.89 | <0.001 | 0.51 | |||||
| Change-of-direction speed (s): | |||||||||
| Lane Agility Drill time: ↑ * | 11.98 ± 0.70 | 12.46 ± 0.75 | <0.05 | −0.61 | |||||
| Linear sprint time (s): | |||||||||
| 5 m sprint time: – | 1.15 ± 0.11 | 1.16 ± 0.08 | >0.05 | −0.09 | |||||
| 10 m sprint time: – | 1.95 ± 0.14 | 1.95 ± 0.12 | >0.05 | 0.00 | |||||
| 20 m sprint time: – | 3.33 ± 0.22 | 3.38 ± 0.21 | >0.05 | −0.21 | |||||
| Repeated-sprint performance (s): | |||||||||
| Suicide run time: ↑ * | 26.49 ± 1.62 | 27.26 ± 1.52 | <0.001 | −0.45 | |||||
| Evening | |||||||||
| Jump height (cm): | |||||||||
| CMJ without arm swing: – | 33.92 ± 6.05 | 33.58 ± 5.84 | >0.05 | 0.05 | |||||
| CMJ with arm swing: – | 42.23 ± 6.06 | 42.89 ± 6.04 | >0.05 | −0.10 | |||||
| Squat jump: – | 32.27 ± 5.06 | 31.74 ± 6.42 | >0.05 | 0.08 | |||||
| Change-of-direction speed (s): | |||||||||
| Lane Agility Drill time: – | 12.61 ± 0.84 | 12.59 ± 0.87 | >0.05 | 0.02 | |||||
| Linear sprint time (s): | |||||||||
| 5 m sprint time: – | 1.08 ± 0.08 | 1.09 ± 0.08 | >0.05 | −0.11 | |||||
| 10 m sprint time: – | 1.86 ± 0.12 | 1.87 ± 0.09 | >0.05 | −0.08 | |||||
| 20 m sprint time: – | 3.27 ± 0.18 | 3.25 ± 0.17 | >0.05 | 0.10 | |||||
| Repeated-sprint performance (s): | |||||||||
| Suicide run time: – | 29.91 ± 1.31 | 29.97 ± 1.63 | >0.05 | −0.04 | |||||
| Tucker et al., 2013 | 5 males [age: 22 ± 1.6 years; body mass: 84.6 ± 8.3 kg; height: 187.4 ± 7.9 cm]; elite level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Tablet containing B1 thiamine | 60 | Reactive strength index (cm/s): | ||||
| Participant A: – | 124 ± 5 | 118 ± 13 | 0.081 | 0.67 | |||||
| Participant B: – | 117 ± 13 | 126 ± 16 | 0.161 | −0.62 | |||||
| Participant C: ↑ * | 119 ± 9 | 109 ± 6 | 0.013 | 1.33 | |||||
| Participant D: – | 111 ± 9 | 122 ± 14 | 0.081 | −0.96 | |||||
| Participant E: – | 87 ± 6 | 83 ± 4 | 0.154 | 0.80 |
Data are reported as mean ± SD. CAF caffeine, PLA placebo, BM body mass, ES effect size, CMJ countermovement jump, RJ-15 15 s maximal jump test, Yo-Yo IR-1 Yo-Yo Intermittent Recovery Level-1, VO2peak peak oxygen uptake, EP end-test power, WEP work done above EP, PO30 averaged power output from 0 to 30 s, PO60 averaged power output from 0 to 60 s, PO90 averaged power output from 0 to 90 s, PO120 averaged power output from 0 to 120 s, PO150 averaged power output from 0 to 150 s, FR fatigue rate, CODAT change of direction and acceleration test, RSA repeated sprint ability, – no change, ↑ increased, * significant change.
Physical performance measures between men and women basketball players following caffeine ingestion.
| Measures (Units) | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of Participants | Change | CAF | PLA | No. of Participants | Change | CAF | PLA | |
| CMJWOAS (cm): | 41 | ↑ | 36.40 ± 5.31 | 34.80 ± 5.12 | 10 | ↑ | 29.20 ± 4.39 | 27.92 ± 4.24 |
| CMJAS (cm): | 11 | ↑ | 42.28 ± 5.88 | 41.44 ± 5.65 | 10 | ↑ | 35.14 ± 5.08 | 33.85 ± 3.92 |
| LAD (s): | 25 | ↑ | 12.05 ± 0.71 | 12.39 ± 0.81 | 10 | ↑ | 12.99 ± 0.86 | 13.22 ± 0.87 |
| 20 m sprint (s): | 25 | ↑ | 3.22 ± 0.19 | 3.28 ± 0.18 | 10 | ↑ | 3.49 ± 0.23 | 3.59 ± 0.25 |
| Suicide run (s): | 11 | ↑ | 28.20 ± 1.47 | 28.62 ± 1.58 | 10 | ↑ | 31.80 ± 16.62 | 32.20 ± 1.74 |
Data are reported as mean ± SD. CAF caffeine, PLA placebo, CMJWOAS countermovement jump without arm swing, CMJAS countermovement jump with arm swing, LAD lane agility drill. ↑ increased.
Effect of caffeine on physiological responses of basketball players.
| References | Participant Profile | Intervention | Administration Mode | Ingestion Time (min) | Measures (Units) & Change | CAF | PLA |
| Hedge’s |
|---|---|---|---|---|---|---|---|---|---|
| Abian-Vicen et al., 2014 | 16 males [age: 14.9 ± 0.8 years; body mass = 73.4 ± 12.4 kg; height = 182.3 ± 6.5 cm]; National Spanish League first division junior team | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Energy drink powder dissolved in 250 mL water | 60 | Perceived muscle power: ↑ * | 7.1 ± 1.1 | 5.2 ± 1.2 | <0.05 | 1.65 |
| Perceived endurance: ↑ * | 6.6 ± 1.4 | 5.1 ± 1.1 | <0.05 | 1.20 | |||||
| Perceived exertion: ↑ * | 4.6 ± 1.8 | 5.7 ± 2.3 | <0.05 | 0.44 | |||||
| Cheng et al., 2016 | 15 males [age: 20 ± 2 years; body mass: 84 ± 12 kg; 188 ± 6 cm]; Division I college level | 6 mg per kg BM CAF or PLA; double-blind, randomized, crossover design | Capsule with 200 mL water | 60 | Peak heart rate (bpm): ↑ * | 172 ± 7 | 165 ± 8 | <0.05 | 0.93 |
| Perceived exertion: – | 18.7 ± 1.5 | 18.7 ± 1.0 | >0.05 | 0.00 | |||||
| Blood lactate (mmol/L): ↑ * | 11.25 ± 2.58 | 9.80 ± 1.76 | <0.05 | 0.67 | |||||
| Puente et al., 2017 | 10 males [age: 27.1 ± 4.0 years] and 10 females [age: 27.9 ± 6.1 years]; professional and semi-professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule | 60 | Heart rate (bpm): | ||||
| Mean: – | 161 ± 10 | 157 ± 13 | 0.229 | 0.35 | |||||
| Maximal: – | 188 ± 10 | 185 ± 12 | 0.499 | 0.27 | |||||
| Perceived exertion (A.U.): – | 4.9 ± 1.5 | 5.3 ± 1.6 | 0.396 | −0.26 | |||||
| Perceived muscle power (A.U.): ↑ * | 6.6 ± 1.4 | 5.3 ± 1.4 | 0.003 | 0.50 | |||||
| Perceived endurance (A.U.): – | 6.3 ± 1.6 | 5.5 ± 1.2 | 0.058 | 0.57 | |||||
| Stojanović et al., 2019 | 10 females [age: 20.2 ± 3.9 years; body mass: 69.2 ± 6.3 kg; height 175.4 ± 5.9 cm]; professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Perceived exertion (AU): ↑ * | 5.6 ± 2.5 | 7.8 ± 1.2 | 0.04 | −1.19 |
| Perceived performance (AU): – | 4.2 ± 2.7 | 3.6 ± 2.8 | 0.53 | 0.22 | |||||
| Stojanović et al., 2021 | 11 males [age: 16.5 ± 1.0 years; body mass: 75.7 ± 7.4 kg; height: 184.7 ± 5.0 cm]; national youth level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Morning | ||||
| Perceived exertion (AU): – | 5.4 ± 1.3 | 6.1 ± 1.8 | >0.05 | −0.45 | |||||
| Perceived performance (AU): – | 6.2 ± 2.6 | 5.7 ± 2.2 | >0.05 | 0.21 | |||||
| Tympanic temperature (°C): ↑ * | 36.2 ± 0.3 | 36.1 ± 0.4 | 0.04 | 0.29 | |||||
| Evening | |||||||||
| Perceived exertion (AU): – | 7.3 ± 1.6 | 7.3 ± 1.5 | >0.05 | 0.00 | |||||
| Perceived performance (AU): – | 4.9 ± 2.0 | 5.7 ± 2.5 | >0.05 | −0.36 | |||||
| Tympanic temperature (°C): ↑ * | 36.6 ± 0.3 | 36.6 ± 0.4 | 0.04 | 0.00 | |||||
| Tan et al., 2020 | 12 males [age: 23.1 ± 1.9 years; body mass: 77.1 ± 12.4 kg; height: 180.1 ± 8.8 cm] and six females [age: 22.0 ± 1.3 yr; body mass: 67.0 ± 11.1 kg; height: 169.4 ± 8.9 cm]; college level | 6 mg per kg BM CAF or PLA; single-blind, randomized design | Caffeine powder dissolved in 300 mL water | 60 | Heart rate (bpm): | ||||
| Set 1: ↑ * | 159 ± 12.2 | 154 ± 15.6 | 0.36 | ||||||
| Set 2: ↑ * | 160 ± 8.7 | 154 ± 10.7 | 0.62 | ||||||
| Set 3: ↑ * | 163 ± 9.7 | 158 ± 11.7 | 0.02 | 0.49 | |||||
| Set 4: – | 162 ± 11.9 | 161 ± 9.4 | 0.09 | ||||||
| Set 5: ↑ * | 166 ± 9.2 | 163 ± 12.1 | 0.28 | ||||||
| Rate of perceived exertion: | |||||||||
| Set 1: – | 10.9 ± 2.3 | 11.7 ± 3.0 | −0.30 | ||||||
| Set 2: – | 12.6 ± 2.0 | 12.5 ± 2.5 | 0.04 | ||||||
| Set 3: – | 13.7 ± 2.1 | 13.4 ± 2.2 | 0.57 | 0.14 | |||||
| Set 4: – | 14.6 ± 1.7 | 14.7 ± 1.9 | −0.06 | ||||||
| Set 5: – | 15.8 ± 2.1 | 15.7 ± 1.9 | 0.05 | ||||||
| Tucker et al., 2013 | 5 males [age: 22 ± 1.6 years; body mass: 84.6 ± 8.3 kg; height: 187.4 ± 7.9 cm]; elite level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Tablet containing B1 thiamine | 60 | Blood lactate (mmol/L): ↑ | NS | NS | NS | NS |
| Heart rate (bpm): NS | NS | NS | NS | NS | |||||
| Rate of Perceived Exertion: | |||||||||
| Overall: – | 12.8 ± 4.0 | 12.8 ± 4.4 | 0.125 | 0.00 | |||||
| Legs: – | 12.9 ± 3.9 | 12.8 ± 4.3 | 0.406 | 0.02 | |||||
| Respiratory Exchange Ratio: | |||||||||
| Participant A: ↑ | NS | NS | <0.001 | NS | |||||
| Participant B: ↑ | NS | NS | <0.001 | NS | |||||
| Participant C: – | NS | NS | 0.75 | NS | |||||
| Participant D: ↑ | NS | NS | <0.001 | NS | |||||
| Participant E: – | NS | NS | 0.58 | NS |
Data are reported as mean ± SD. CAF caffeine, PLA placebo, BM body mass, ES effect size, bpm beats per minute, A.U. arbitrary units, °C degree Celsius, NS not specified, – no change, ↑ increased, * significant change.
Effect of caffeine on physical and basketball performance across different genetic types.
| References | Participant Profile | Intervention | Administration Mode | Ingestion Time (min) | Measures (Units) & Change | CAF | PLA |
| Hedge’s |
|---|---|---|---|---|---|---|---|---|---|
| Puente et al., 2018 | 10 AA homozygotes [age: 26.7 ± 3.5 years; body mass: 83.5 ± 19.2 kg; height: 187.6 ± 16.7 cm] and 9 C-allele carriers [age: 29.4 ± 6.0 yr; body mass: 78.4 ± 14.7 kg; height: 182.8 ± 16.7 cm]; professional and semi-professional level | 3 mg per kg BM CAF or PLA; double-blind, randomized design | Capsule | 60 | Mean Abalakov jump height (cm): | ||||
| AA homozygotes: ↑ * | 40.7 ± 7.3 | 39.6 ± 7.2 | 0.03 | 0.15 | |||||
| C-allele carriers: – | 37.2 ± 6.9 | 36.3 ± 5.9 | 0.33 | 0.14 | |||||
| CODAT without the ball (s): | |||||||||
| AA homozygotes: – | 5.88 ± 0.27 | 5.91 ± 0.25 | 0.36 | −0.12 | |||||
| C-allele carriers: – | 5.97 ± 0.38 | 5.95 ± 0.33 | 0.37 | 0.06 | |||||
| CODAT with the ball (s): | |||||||||
| AA homozygotes: – | 6.09 ± 0.24 | 6.19 ± 0.21 | 0.15 | −0.44 | |||||
| C-allele carriers: – | 6.14 ± 0.41 | 6.14 ± 0.35 | 0.49 | 0.00 | |||||
| Mean heart rate (bpm): | |||||||||
| AA homozygotes: – | 160 ± 10 | 158 ± 9 | 0.72 | 0.21 | |||||
| C-allele carriers: – | 163 ± 9 | 161 ± 13 | 0.82 | 0.18 | |||||
| Peak heart rate (bpm): | |||||||||
| AA homozygotes: – | 188 ± 13 | 187 ± 12 | 0.22 | 0.08 | |||||
| C-allele carriers: – | 185 ± 6 | 182 ± 7 | 0.46 | 0.23 | |||||
| Perceived muscle power (A.U.): | |||||||||
| AA homozygotes: ↑ * | 6.7 ± 1.3 | 5.3 ± 1.8 | 0.04 | 0.90 | |||||
| C-allele carriers: – | 6.2 ± 1.5 | 5.4 ± 0.9 | 0.16 | 0.67 | |||||
| Perceived exertion (A.U.): | |||||||||
| AA homozygotes: – | 4.6 ± 1.5 | 5.3 ± 1.6 | 0.20 | −0.45 | |||||
| C-allele carriers: – | 5.4 ± 1.5 | 5.4 ± 1.5 | 0.50 | 0.00 | |||||
| Perceived endurance (A.U.): | |||||||||
| AA homozygotes: – | 6.8 ± 1.5 | 5.7 ± 1.6 | 0.06 | 0.71 | |||||
| C-allele carriers: – | 5.6 ± 1.7 | 5.6 ± 0.9 | 0.50 | 0.00 |
Data are reported as mean ± SD. CAF caffeine, PLA placebo, BM body mass, ES effect size, bpm beats per minute, A.U. arbitrary units, —no change, ↑ increased, * significant change.
Side effects of caffeine during basketball testing studies.
| References | Participant Profile | Intervention | Administration Mode | Ingestion Time (min) | Side Effects | CAF (%) | PLA (%) |
|---|---|---|---|---|---|---|---|
| Abian-Vicen et al., 2014 | 16 males [age: 14.9 ± 0.8 years; body mass = 73.4 ± 12.4 kg; height = 182.3 ± 6.5 cm]; National Spanish League first division junior team | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Energy drink powder dissolved in 250 mL water | 60 | Headache: | 6.3 | 12.5 |
| Abdominal discomfort: | 12.5 | 6.3 | |||||
| Muscle soreness: | 31.3 | 25 | |||||
| Increased activeness: | 37.5 | 0 | |||||
| Tachycardia and heart palpitations: | 0 | 0 | |||||
| Insomnia: | 12.5 | 0 | |||||
| Increased urine production: | 0 | 0 | |||||
| Increased anxiety: | 0 | 0 | |||||
| Puente et al., 2017 | 10 males [age: 27.1 ± 4.0 years] and 10 females [age: 27.9 ± 6.1 years]; professional and semi-professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule | 60 | Insomnia: | 54.4 | 19.0 |
| Nervousness: | NS | NS | |||||
| Irritability: | NS | NS | |||||
| Activeness: | NS | NS | |||||
| Gastrointestinal discomfort: | NS | NS | |||||
| Headache: | NS | NS | |||||
| Muscle pain: | NS | NS | |||||
| Puente et al., 2018 | 10 AA homozygotes [age: 26.7 ± 3.5 years; body mass: 83.5 ± 19.2 kg; height: 187.6 ± 16.7 cm] and 9 C-allele carriers [age: 29.4 ± 6.0 yr; body mass: 78.4 ± 14.7 kg; height: 182.8 ± 16.7 cm]; professional and semi-professional level | 3 mg per kg BM CAF or PLA; double-blind, randomized design | Capsule | 60 | Nervousness: | ||
| AA homozygotes | 20 | 10 | |||||
| C-allele carriers: | 0 | 11 | |||||
| Insomnia: | |||||||
| AA homozygotes | 70 | 20 | |||||
| C-allele carriers: | 33 | 22 | |||||
| Gastrointestinal complaints: | |||||||
| AA homozygotes | 20 | 0 | |||||
| C-allele carriers: | 0 | 0 | |||||
| Activeness: | |||||||
| AA homozygotes | 30 | 20 | |||||
| C-allele carriers: | 11 | 11 | |||||
| Muscle pain: | |||||||
| AA homozygotes | 10 | 30 | |||||
| C-allele carriers: | 11 | 11 | |||||
| Headache: | |||||||
| AA homozygotes | 0 | 10 | |||||
| C-allele carriers: | 0 | 11 | |||||
| Raya-González et al., 2021 | 14 males [age: 21 ± 2 years; body mass: 87 ± 6 kg; height 190 ± 5 cm]; professional level | 6 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized, crossover design | Supplement dissolved in 250 mL water | 60 | Insomnia: | 57 | 14 |
| Tachycardia: | 14 | 0 | |||||
| Anxiety: | 0 | 0 | |||||
| Abdominal discomfort: | 21 | 14 | |||||
| Headache: | 0 | 7 | |||||
| Activeness: | 21 | 7 | |||||
| Muscle soreness: | 7 | 14 | |||||
| Urine output: | 50 | 7 | |||||
| Stojanović et al., 2019 | 10 females [age: 20.2 ± 3.9 years; body mass: 69.2 ± 6.3 kg; height 175.4 ± 5.9 cm]; professional level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Headache: | 10 | 20 |
| Abdominal discomfort: | 20 | 10 | |||||
| Muscle soreness: | 10 | 0 | |||||
| Increased activeness: | 30 | 0 | |||||
| Tachycardia: | 30 | 10 | |||||
| Insomnia: | 10 | 20 | |||||
| Increased urine production: | 10 | 10 | |||||
| Increased anxiety: | 0 | 10 | |||||
| Stojanović et al., 2021 | 11 males [age: 16.5 ± 1.0 years; body mass: 75.7 ± 7.4 kg; height: 184.7 ± 5.0 cm]; national youth level | 3 mg per kg BM CAF or PLA; double-blind, counterbalanced, randomized design | Capsule with 250 mL water | 60 | Morning | 9 | 0 |
| Headache: | 0 | 0 | |||||
| Abdominal discomfort: | 9 | 0 | |||||
| Muscle soreness: | 18 | 18 | |||||
| Increased activeness: | 0 | 0 | |||||
| Tachycardia: | 9 | 9 | |||||
| Insomnia: | |||||||
| Increased urine production: | 9 | 0 | |||||
| Increased anxiety: | 0 | 0 | |||||
| Evening | 9 | 9 | |||||
| Headache: | 18 | 9 | |||||
| Abdominal discomfort: | 18 | 9 | |||||
| Muscle soreness: | 9 | 27 | |||||
| Increased activeness: | 27 | 9 | |||||
| Tachycardia: | 0 | 0 | |||||
| Insomnia: | |||||||
| Increased urine production: | 45 | 9 | |||||
| Increased anxiety: | 0 | 9 |
CAF caffeine, PLA placebo, BM body mass.